NovaBay Pharmaceuticals: A Potential Bargain With Catalysts Pending

By VFC: Keep an eye on NovaBay Pharmaceuticals (AMEX: NBY) to close out 2011, as trading volume has quietly been picking up steam, as noted here last week.

By VFC: Shares of NovaBay Pharmaceuticals (NBY) looked like quite the attractive speculative buy just days ago, when company shares saw the stock trade for right around ninety cents.

By VFC: Shares of NovaBay Pharmaceuticals (NBY) were cruising along for months in a price range pretty much centered at right around the $1.30 mark until a sudden slide took shape along as the general market started to experience an overall downturn. No news hit the streets to justify the share price drop and volume, while above the norm, did not indicate a mass exodus of any sort.

By VFC: Success for a small biotech or developing pharmaceutical company is often measured not only by the technology of its pipeline, but also by the ability of a company to position itself to be in the right place at an opportune time.

By John H. Ford:Oculus Innovative Sciences (OCLS) and NovaBay Pharmaceuticals (NBY) offer investors potential short-term returns well over 100%. I expect Oculus in particular to perform even better than some of my recent picks. For example:

By VFC: Synergy Pharmaceuticals (SGYP) has numerous catalysts pending for the remainder of 2012 and could be gearing up to make a splash in the healthcare and pharmaceutical sectors as those catalysts unfold.

ByLouis Dematteis:Biotechnology stocks continue to be some of the strongest performers in the markets as favorable legislation, such as the FAST and TREAT acts, have helped boost investor optimism. One of the most promising approaches in biotechnology is immunotherapy.

BySteven Barnes: Novabay Pharmaceuticals has good news that could boost its value.